Evidence map›Paper›PMID 35028368›Full record

ArticleInternational journal of women's dermatology2021

Impact of psoriatic disease on women aged 18 to 45: Results from a multinational survey across 11 European countries.

Sandy R McBride, Maria C Fargnoli, Anne-Claire Fougerousse, Marta García Bustínduy, Louise Catton, Lerzan Senturk, Cécile Ecoffet, Jan Koren, Laura Andreoli, Laura C Coates and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of women's dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 5 countries.

Sandy R McBrideDepartment of Dermatology, Royal Free London NHS Foundation Trust, London, United Kingdom.
Maria C FargnoliDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Anne-Claire FougerousseDepartment of Dermatology, GEM ResoPso, Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France.
Marta García BustínduyDepartment of Internal Medicine, Dermatology and Psychiatry, Universidad de La Laguna, San Cristobal de La Laguna, Spain.
Louise CattonUCB Pharma, Slough, United Kingdom.
Lerzan SenturkUCB Pharma, Brussels, Belgium.
Cécile EcoffetUCB Pharma, Brussels, Belgium.
Jan KorenEUROPSO, Polzela, Slovenia.
Laura AndreoliDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
Alice TitialiiInternational Federation of Psoriasis Associations, Stockholm, Sweden.
UCB Pharma (Belgium) · BEAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITHôpital d'Instruction des Armées Bégin · FRNuffield Orthopaedic Centre · GBRoyal Free London NHS Foundation Trust · GBUCB Pharma (United Kingdom) · GBUniversidad de La Laguna · ESUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlaque psoriasis (PSO) is a long-term inflammatory condition that can cause concomitant joint symptoms (psoriatic arthritis [PsA]) in up to 30% of patients. The impact of psoriatic disease on disease outcomes and quality of life is greater in women than men.

objectiveWe evaluated the impact of psoriatic disease on women aged 18 to 45 years across Europe.

methodsWomen aged 18 to 45 years with moderate to severe PSO, PsA, or PSO + PsA (PSO with progression to PsA) and prior biologic experience were recruited from market research panels and patient association groups of the International Federation of Psoriasis Associations, European Federation of Psoriasis Patient Associations, and Arthritis Ireland and asked to complete a survey. Questions covered social and psychological wellbeing, employment, and family planning. Question types included 5- or 7-point agreement scales, where the highest/lowest two ratings were considered agreement/disagreement, respectively. The results are reported as proportions of those who selected the answer, divided by overall respondents for each question. Women were not required to answer all questions.

resultsSurvey respondents (N = 573) had a diagnosis of PSO (n = 236), PsA (n = 173), or PSO + PsA (n = 164). Women self-reported similar mean scores for physical (57.0 of 100) and mental (59.0 of 100) health. A fifth (21%) had not achieved their desired career due to PSO/PsA; career dissatisfaction and increased sick leave were linked to poor mental health. Some women reported having a limited social life (33%), smaller families (34%), and being more likely to adopt children (27%) due to PSO/PsA. A quarter of women (27%) reported not understanding enough about PSO/PsA (nonmembers vs. members of patient association groups: 37% vs. 8%).

conclusionOur findings highlight the considerable burden of psoriatic disease on women of childbearing age. Increased provision of information tailored to women, training for health care professionals, and shared decision-making between patients and health care professionals may help better support women with psoriatic disease.

Indexed as

family planningmental healthPsoriasispsoriatic arthritiswomen of childbearing age

Identifiers

PMID35028368
PMCPMC8714576
OpenAlexW3197496367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.